Anika Therapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $57.5M | $55.6M | $68.7M | $86.3M | $94.4M | $95.8M | $157.5M | $89.0M |
| Accounts Receivable | $23.7M | $23.6M | $26.4M | $34.6M | $29.8M | $24.1M | $23.1M | $20.8M |
| Inventory | $18.8M | $23.8M | $24.4M | $39.8M | $36.0M | $46.2M | $22.0M | $21.3M |
| Total Current Assets | $103.4M | $113.7M | $163.3M | $169.5M | $168.5M | $177.4M | $234.3M | $202.9M |
| Property, Plant & Equipment | $40.3M | $39.0M | $37.4M | $48.3M | $47.6M | $50.6M | $50.8M | $54.1M |
| Goodwill | $8.1M | $7.1M | $7.6M | $7.3M | $7.8M | $8.4M | $7.7M | $7.9M |
| Intangible Assets (Excl. Goodwill) | $1.7M | $2.5M | $2.6M | $74.6M | $82.4M | $91.2M | $7.6M | $9.2M |
| Total Assets | $190.3M | $202.7M | $270.6M | $349.1M | $347.5M | $365.6M | $330.7M | $279.0M |
| Liabilities | ||||||||
| Accounts Payable | $6.0M | $5.6M | $6.2M | $9.1M | $7.6M | $9.0M | $3.8M | $3.1M |
| Total Current Liabilities | $21.9M | $23.3M | $31.1M | $27.9M | $29.8M | $36.9M | $16.3M | $11.3M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $46.8M | $48.8M | $58.4M | $63.6M | $60.5M | $93.2M | $42.3M | $15.4M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $60.8M | $71.7M | $128.1M | $210.7M | $225.6M | $221.4M | $245.4M | $218.2M |
| Total Stockholders' Equity | $143.5M | $154.0M | $212.3M | $285.6M | $287.1M | $272.4M | $288.4M | $263.6M |